Oramed keeps up the pace in oral insulin race

9 May 2019

A first-of-its-kind trial of oral insulin being spearheaded by Israeli diabetes specialist Oramed Pharmaceuticals (Nasdaq: ORMP) is now taking place at 37 research centers across the USA.

Clinics in 13 states are testing this form of insulin on nearly 300 Americans that could delay, and in some cases may even negate, the need for use of needles for many type 2 diabetics.

Oramed, which is based in both the USA and Israel, wants to be the first to take this form of the drug to market and the trial is its largest and most advanced to date under the direction of the US Food and Drug Administration.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK